U.S. Luxury Stock News

With a median price-to-sales (or "P/S") ratio of close to 1.1x in the Energy Services industry in the United States...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Playboy, Inc. ( NASDAQ:PLBY ) shares have retraced a considerable 26% in the last month, reversing a fair amount of...

Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right...

Those holding Coeur Mining, Inc. ( NYSE:CDE ) shares would be relieved that the share price has rebounded 26% in the...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Copart, Inc.'s ( NASDAQ:CPRT ) price-to-earnings (or "P/E") ratio of 23.2x might make it look like a sell right now...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...

Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...

Cybin (NasdaqGM:HELP) has entered the Nasdaq Composite Index following its rebrand to Helus Pharma and uplisting to Nasdaq. This development aligns with its late stage neuropsychiatry drug programs and commercialization plans. See our latest analysis for Cybin. The recent rebrand, uplisting and index inclusion come after a mixed run for investors, with a 23.18% 1 month share price return and a 16.11% 3 month share price return. This contrasts with a 23.85% 1 year total shareholder return...

TrustRadius awards put Verint Systems (VRNT) in focus Verint Systems (VRNT) recently picked up two TrustRadius 2026 Buyer’s Choice awards, including recognition in the Contact Center category. The awards have brought fresh attention to how its AI powered customer experience tools might relate to the stock. See our latest analysis for Verint Systems. Despite the TrustRadius recognition, Verint Systems’ share price return has been weak over the year, with a year to date share price return...

Lotus Technology Inc. has replaced its independent auditor, dismissing KPMG Huazhen LLP and appointing Grant Thornton Zhitong Certified Public Accountants LLP to audit its consolidated financial statements for the fiscal year ended December 31, 2025. This shift in audit oversight is important for investors because it can influence confidence in the company’s financial reporting quality and governance practices. We’ll now explore how this auditor change might influence Lotus Technology’s...

Q1 2026 earnings snapshot UniFirst (UNF) opened its new fiscal year with Q1 2026 results anchored by prior quarter revenue of US$614.4 million and basic EPS of US$2.23, with trailing twelve month EPS at US$8.01 on US$2.4 billion of revenue and net income of US$148.3 million. Over recent quarters the company has seen revenue move from US$603.3 million in Q3 2024 to US$604.9 million in Q1 2025 and then to US$610.8 million and US$614.4 million in Q3 and Q4 2025, while quarterly EPS has tracked...

Understanding Chime Financial’s Recent Share Performance Chime Financial (CHYM) has recently drawn investor attention after a period of relatively strong share price performance, with the stock showing positive returns over the past week, month and past 3 months. See our latest analysis for Chime Financial. At a share price of $27.23, Chime Financial’s short term momentum has been firm, with a 30 day share price return of 13.84% and a 90 day share price return of 27.99%, while the year to...

In the third quarter of 2025, Allot reported that its Cybersecurity-as-a-Service (SECaaS) annual recurring revenue grew about 60% year over year, increasingly making SECaaS the company’s primary growth engine through stronger adoption by telecom partners and end users. This acceleration in SECaaS, now expected by management to move toward roughly 30% of total revenue, suggests a greater tilt toward recurring, subscription-based income streams that can reshape Allot’s overall revenue mix and...

Apogee Enterprises Q3 2026 Earnings Snapshot Apogee Enterprises (APOG) has just turned in another data point in a volatile stretch, with recent quarterly revenue sitting at about US$358.2 million and basic EPS of roughly US$1.10, against a trailing twelve month picture that shows total revenue of about US$1.39 billion and EPS of roughly US$2.07. Over the last few reported quarters, the company has seen revenue move from about US$331.5 million and EPS of roughly US$1.42 in early 2025 to the...

AAR Corp. (AIR) has reported results for Q2 2026, with revenue of US$795.3 million and basic EPS of US$0.92, alongside trailing twelve month EPS of US$2.59 and net income of US$94.1 million. The company’s revenue has increased from US$686.1 million in Q2 2025 to US$795.3 million in Q2 2026, while quarterly EPS has moved from a loss of US$0.87 to a profit of US$0.92. This represents a very large year-over-year earnings improvement that feeds into forecasts calling for about 34.7% annual...

Wondering whether Protagonist Therapeutics at around US$82 per share is still offering value, or if the best part of the opportunity has passed? This article is aimed at helping you frame that question clearly. The stock has been volatile in the short term, with a 5.8% decline over the last week and an 8.9% decline over the last month, even though the 1 year return stands at 118.6% and the 5 year return at 285.6%. These sharp moves come against a backdrop of ongoing interest in Protagonist...

Rayonier stock: recent performance snapshot Rayonier (RYN) has attracted fresh attention after recent trading left the shares at US$21.66, with returns near flat over the past week and a negative move over the past 3 months and year. See our latest analysis for Rayonier. At the current share price of US$21.66, Rayonier’s recent drift lower, including a 17.45% 3 month share price decline and a 6.67% 1 year total shareholder return decline, points to fading momentum as investors reassess its...

If you are wondering whether Leonardo DRS is still reasonably priced after its recent run, this article walks through what the current numbers may imply about value. The stock most recently closed at US$37.20, with returns of 9.1% over 7 days, 9.7% over 30 days, 7.0% year to date and 12.9% over the past year, as well as a very large 3 year return of 194.0%. Recent coverage has focused on Leonardo DRS as a US defense and electronics business, with investors watching how its positioning in...

PriceSmart, Inc. has released its fiscal first-quarter 2026 results, reporting net income of US$40.2 million, earnings of US$1.29 per share, and revenue of US$1.38 billion from its 56 warehouse clubs across 12 countries and one U.S. territory. The company also highlighted 8.0% comparable net merchandise sales growth and outlined plans to expand to 60 clubs, including a tenth location in Costa Rica, underscoring continued emphasis on club rollouts in existing markets. Next, we’ll examine how...

If you are wondering whether Tandem Diabetes Care's share price still reflects its true worth, you are not alone. The stock has drawn attention from investors who are trying to work out if the current level makes sense. The shares last closed at US$23.54, with recent returns of 4.6% over 7 days, 12.5% over 30 days and 9.2% year to date, set against a 36.5% decline over 1 year, a 47.0% decline over 3 years, and a 74.7% decline over 5 years. Recent attention on Tandem Diabetes Care has been...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...